Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.58 |
| ▸ | CDK1 | P06493 | 6/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.58 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.58 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.58 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.58 |
| ▸ | CDK9 | P50750 | 4/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1197602 | 0.87 | AURKA (0.60) | CDK2CDK1CCNB1CCNB2CDK5 | |
| SCHEMBL4008247 | 0.84 | AURKA (0.59) | CDK2CDK1CCNB1CCNB2CDK5 | |
| SCHEMBL28059063 | 0.83 | CDK1 (0.54) | CDK2CDK1CCNB1CCNB2CDK5 | |
| SCHEMBL3996202 | 0.78 | JAK3 (0.60) | CDK2CDK1CCNB1CCNB2CDK5 | |
| SCHEMBL4001420 | 0.78 | AURKA (0.59) | CDK2CDK1CCNB1CCNB2CDK5 | |
| SCHEMBL12749886 | 0.77 | AURKA (0.45) | CDK2CDK1CCNB1CCNB2CDK5 | |
| SCHEMBL3997330 | 0.77 | AURKA (0.58) | CDK2CDK1CCNB1CCNB2CDK5 | |
| SCHEMBL4006193 | 0.75 | JAK3 (0.59) | CDK2CDK1CCNB1CCNB2CDK5 | |
| SCHEMBL4002720 | 0.74 | SYK (0.64) | CDK2CDK1CDK5CCNE1CCNT1 | |
| SCHEMBL4003171 | 0.74 | AURKA (0.52) | CDK2CDK1CCNB1CCNB2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593082-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | CDK2 986/4885CDK1 537/4885CCNB1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.